摘要
目的探讨雷贝拉唑联合黛力新治疗非糜烂性胃食管反流病的疗效。方法 80例非糜烂性胃食管反流病患者随机分为对照组(40例)和实验组(40例)。所有患者生活方式干预一致,对照组采用雷贝拉唑20 mg,每天2次,口服8周;实验组采用雷贝拉唑20 mg,每天2次,黛力新,10.5 mg,每天1次,口服8周,8周后比较两组疗效。结果实验组40例中显效28例,有效9例,无效3例,总有效率92.5%(37/40);对照组40例中显效17例,有效8例,无效15例,总有效率62.5%(25/40)。两组比较差异有统计学意义(P<0.05)。结论雷贝拉唑联合黛力新治疗比单纯用雷贝拉唑治疗可更有效地改善非糜烂性胃食管反流病患者的临床症状。
Objective To investigate the therapeutic effects of the combined treatment of Rabeprazole and Deanxit on patients with non-erosive gastroesophageal reflux disease(NERD).Methods A total of 80 NERD patients were divided into control group(n=40)and test group(n=40).Test group were given Rabeprazole(20 mg,bid)and Daenxit(10.5mg,qd)for 8 weeks.Control group were given Rabeprazole(20 mg,bid)for 8 weeks,Chi-square test was conducted to compare the efficacy between the two groups.Results In the test group,notable efficacy was found in 28 cases,effectivity in 9 cases,and inefficacy in 3 cases and the total effective rate was 92.5%(37/40).In the control group,notable efficacy was observed in 17 cases,effectivity in 8 cases,and inefficacy in 15 cases are ineffective,and the total effective rate was 62.5%(25/40).There was significant difference between the two groups(P<0.05).Conclusion The combined treatment of Rabeprazole and Deanxit can improve the clinical symptoms of NERD patients more effectively.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2014年第S2期28-29,共2页
Chinese Journal of Practical Internal Medicine
